We are live on ! Find out more
INDP icon

Indaptus Therapeutics
INDP

16 hedge funds and large institutions have $839K invested in Indaptus Therapeutics in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0% more ownership

Funds ownership: 0.25% → 0.25% (+0%)

6% less funds holding

Funds holding: 17 → 16 (-1)

31% less capital invested

Capital invested by funds: $1.22M → $839K (-$384K)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
16
Holders Change
-1
Holders Change %
-5.88%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$26.2K
2
TRCT
Tower Research Capital (TRC)
New York
+$11.6K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$202
4
Wells Fargo
Wells Fargo
California
+$51

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$24K
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.11K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$202
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$363K +$202 +4 +0%
IHL
2
Investment House LLC
California
$139K – – –
SAM
3
Strategy Asset Managers
California
$80K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$72K -$202 -4 -0.2%
SWP
5
Stratos Wealth Partners
Ohio
$38.9K – – –
VCM
6
Vivaldi Capital Management
Illinois
$38.4K – – –
State Street
7
State Street
Massachusetts
$28K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$28K -$1.11K -22 -3%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$20.9K +$26.2K +518 New
Northern Trust
10
Northern Trust
Illinois
$18.7K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$10K +$11.6K +229 +1,908%
BSB
12
Bangor Savings Bank
Maine
$1K – – –
Morgan Stanley
13
Morgan Stanley
New York
$767 – – –
Wells Fargo
14
Wells Fargo
California
$142 +$51 +1 +33%
Bank of America
15
Bank of America
North Carolina
$16 – – –
Group One Trading
16
Group One Trading
Illinois
$10 – – –
Citadel Advisors
17
Citadel Advisors
Florida
– -$24K -389 Closed

INDP Hedge Fund Activity: Q4 2022 in Review

16 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q4 2022, worth a combined $839K — down 31% from $1.22M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of INDP and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $26.2K. The largest seller was Citadel Advisors, exiting entirely with an estimated $24K sold.

  • 16 institutional investors held Indaptus Therapeutics (INDP) as of Q4 2022, down from 17 in Q3 2022.
  • Funds reported $839K of Indaptus Therapeutics stock for Q4 2022, down 31% quarter-over-quarter.
  • 1 fund opened new Indaptus Therapeutics positions in Q4 2022 and 2 closed out, a net change of -1 holder.
  • The largest Indaptus Therapeutics buyer in Q4 2022 was Susquehanna International Group, an estimated $26.2K added.
  • The largest Indaptus Therapeutics seller in Q4 2022 was Citadel Advisors, an estimated $24K sold.

Based on aggregated 13F filings for Q4 2022.